Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

Ascher-Svanum, Haya; Baojin Zhu; Faries, Douglas; Landbloom, Ron; Swartz, Marvin; Swanson, Jeff
January 2006
BMC Psychiatry;2006, Vol. 6, p8
Academic Journal
Background: There is an ongoing debate over whether atypical antipsychotics are more effective than typical antipsychotics in the treatment of schizophrenia. This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index of medication effectiveness in the treatment of schizophrenia. Methods: We used data from a large, 3-year, observational, non-randomized, multisite study of schizophrenia, conducted in the U.S. between 7/1997 and 9/2003. Patients who were initiated on oral atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine, or ziprasidone) or oral typical antipsychotics (low, medium, or high potency) were compared on time to all-cause medication discontinuation for 1 year following initiation. Treatment group comparisons were based on treatment episodes using 3 statistical approaches (Kaplan-Meier survival analysis, Cox Proportional Hazards regression model, and propensity score-adjusted bootstrap resampling methods). To further assess the robustness of the findings, sensitivity analyses were performed, including the use of (a) only 1 medication episode for each patient, the one with which the patient was treated first, and (b) all medication episodes, including those simultaneously initiated on more than 1 antipsychotic. Results: Mean time to all-cause medication discontinuation was longer on atypical (N = 1132, 256.3 days) compared to typical antipsychotics (N = 534, 197.2 days; p < .01), and longer on atypicals compared to typicals of high potency (N = 320, 187.5 days; p < .01), medium potency (N = 140, 213.5 days; p < .01), and low potency (N = 74, 208.7 days; p < .01). Among the atypicals, only clozapine, olanzapine, and risperidone had significantly longer time to all-cause medication discontinuation compared to typicals, regardless of potency level, and compared to haloperidol with prophylactic anticholinergic treatment. When compared to perphenazine, a medium-potency typical antipsychotic, only clozapine and olanzapine had a consistently and significantly longer time to all-cause medication discontinuation. Results were confirmed by sensitivity analyses. Conclusion: In the usual care of schizophrenia patients, time to medication discontinuation for any cause appears significantly longer for atypical than typical antipsychotics regardless of the typical antipsychotic potency level. Findings were primarily driven by clozapine and olanzapine, and to a lesser extent by risperidone. Furthermore, only clozapine and olanzapine therapy showed consistently and significantly longer treatment duration compared to perphenazine, a medium-potency typical antipsychotic.


Related Articles

  • zotepine.  // Royal Society of Medicine: Medicines;2002, p580 

    This article presents information on zotepine, an antipsychotic drug which can be used for the treatment of schizophrenia. It is taken orally.

  • Effects of long-term treatment with antipsychotics on serum leptin levels. Herrán, Andrés; García-Unzueta, María Teresa; Amado, José Antonio; de la Maza, María Teresa; Álvarez, Concepción; Vázquez-Barquero, José Luis // British Journal of Psychiatry;Jul2001, Vol. 179, p59 

    Background Abnormal regulation of the adipocyte-derived hormone leptin could play a role in body weight gain induced by antipsychotics. Aims To study the effects of long-term antipsychotic treatment on leptin levels in patients with schizophrenia. Method Serum leptin levels were determined in 59...

  • Case Histories Illustrating the Utility of Sertindole in Clinical Practice. Schuck, Peter; Ameele, Hans van den; Jaanson, Peeter; Ryckmans, Vincent; Hawley, Chris // CNS Drugs;2004 Supplement 2, Vol. 18, p31 

    Many conventional and atypical antipsychotic agents are available for the treatment of schizophrenia. Matching individual patients to the medication that suits them best is often a matter of trial and error. Controlled clinical trials and extensive post-marketing research have shown that the...

  • Clopixol.  // Royal Society of Medicine: Medicines;2002, p162 

    The article presents information on Clopixol, a proprietary, prescription-only preparation of the antipsychotic zuclopenthixol dihydrochloride, and can be used for the long-term maintenance of schizophrenia and other psychoses. It is available as tablets and a depot deep intramuscular injection...

  • amisulpride.  // Royal Society of Medicine: Medicines;2002, p52 

    The article provides information on amisulpride, an antipsychotic drug which can be used for the treatment of symptoms of schizophrenia, often in patients who do not respond to, or who can not tolerate, conventional antipsychotic drugs. It is taken orally. Atypical antipsychotics are used with...

  • Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial. Gharabawi, Georges M.; Greenspan, Andrew; Rupnow, Marcia F. T.; Kosik-Gonzalez, Colette; Bossie, Cynthia A.; Young Zhu; Kalali, Amir H.; Awad, A. George // BMC Psychiatry;2006, Vol. 6, p45 

    Background: Patient satisfaction with antipsychotic treatment is important. Limited evidence suggests that satisfaction is associated with symptom improvement and compliance. Predictors of patient satisfaction with antipsychotic medication were examined in a study of patients with a recent...

  • Dopamine and antipsychotic drug action revisited. Jones, H. M.; Pilowsky, L. S. // British Journal of Psychiatry;Oct2002, Vol. 181, p271 

    The article discusses the dopamine hypothesis of antipsychotic drug action as well as review studies that have elaborated understanding of its relevance. The authors look into the dopaminergic pathways and receptor physiology and highlights that D2 receptors in schizophrenia were crucial to the...

  • Antipsychotic medication and the death penalty. Williams, Karl G. // American Journal of Health-System Pharmacy;5/15/2006, Vol. 63 Issue 10, p966 

    The article discusses the treatment of schizophrenic patients with antipsychotic medication. Since antipsychotics can cause severe adverse effects, society has struggled with the issue of whether these patients have the right to reject such medication. Another layer of difficulty is added when...

  • Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia. Harvey, Philip D.; McClure, Margaret M. // Drugs;2006, Vol. 66 Issue 11, p1465 

    Cognitive dysfunction is a core feature of schizophrenia as deficits that are present in the majority of patients with schizophrenia frequently precede the onset of other symptoms and persist even after other symptoms have been effectively treated. The use of atypical antipsychotics has produced...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics